Trial Profile
A Two Part Study to Investigate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2339345 in Healthy Subjects. Part A: an Open Label, Dose Escalating, Rinse, Gargle and Spit Study. Part B: a Randomised, Double-blind, Placebo Controlled, Inhaled Dose Escalating Study Using Nebulised Lidocaine for Blinding Purposes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2339345 (Primary) ; GSK 2339345 (Primary)
- Indications Cough
- Focus Adverse reactions; Pharmacodynamics
- Acronyms FTIH
- Sponsors GlaxoSmithKline; GSK
- 17 Jun 2014 New trial record